Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ATAthira Pharma, Inc. logo

Athira Pharma, Inc. (ATHA)

NASDAQ Global Select · Currency in USD
$6.75 ▼ -0.44 (-6.12%)
At close: Jan 9, 4:00 PM ET. Market closed.
$6.95 ▲ +0.20 (+2.96%)
After hours: Jan 9, 7:03 PM ET

Summary

Previous Close
$7.19
Open
$7.30
Day's Range
$6.61 – $7.35
52 Week Range
$2.20 – $8.36
Volume
70,313
Avg. Volume
1,056,070
Market Cap
$26.62M
Beta (5Y Monthly)
2.80
PE Ratio (TTM)
--
EPS (TTM)
-$5.96
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$13.33

Profile: Athira Pharma, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
26
CEO
Mark J. Litton

Athira Pharma, Inc., a biopharmaceutical firm in advanced clinical development and based in Bothell, Washington, focuses on creating small molecule treatments designed to revitalize neuronal function and decelerate neurological decline. Its primary therapeutic candidate, ATH-1017, is a unique small molecule that modulates HGF/MET and is capable of crossing the blood-brain barrier. This compound is currently undergoing a Phase 3 clinical trial (LIFT-AD) and a Phase 2 clinical trial (ACT-AD) for Alzheimer's disease.

Earnings

DateEst.Actual
Aug 14, 2026-$0.60-$0.80Miss
May 7, 2026-$1.90-$1.73Beat
Feb 25, 2026-$0.58-$18.94Miss
Nov 6, 2025-$1.06-$1.68Miss
Aug 7, 2025-$1.80-$1.80Beat
May 9, 2025-$2.00-$2.30Miss

Analyst view

Consensus price target
$13.33 ▲ +97.5%
Range $3.00 – $33.00
Rating: Hold
Buy 0% · Hold 100% · Sell 0%

Get free alerts on ATHA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.